619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster I

A plasma based test for the measurable residual disease informs the response to treatment in AML patients

Prognostic impact of MRD negativity in AML patients treated with venetoclax based therapy A systematic review and meta analysis

CD48 as an additional marker for measurable residual disease assessment in pediatric Acute Myeloid Leukemia

Residual mutations in epigenetic modifiers are associated with poor prognosis and high relapse rate in Acute Myeloid Leukemia

Early flow cytometry based MRD predicts relapse in intermediate risk AML from low and middle income countries

Outcomes following MRD relapse in AML patients monitored by droplet digital PCR